{"id":50487,"date":"2022-11-04T07:02:35","date_gmt":"2022-11-04T06:02:35","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/benevolentai-to-present-at-jefferies-investor-conference-in-november\/"},"modified":"2022-11-04T07:02:35","modified_gmt":"2022-11-04T06:02:35","slug":"benevolentai-to-present-at-jefferies-investor-conference-in-november","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/benevolentai-to-present-at-jefferies-investor-conference-in-november\/","title":{"rendered":"BenevolentAI to present at Jefferies Investor Conference in November"},"content":{"rendered":"
\n

LONDON–(BUSINESS WIRE)–BenevolentAI \u200b\u200b(Euronext Amsterdam: BAI), a leading clinical-stage AI drug discovery company, announces that it will participate at the upcoming Jefferies London Healthcare Conference from 15-17 November.\n<\/p>\n

\nNick Keher, Chief Financial Officer of BenevolentAI is scheduled to present at 10.20 AM GMT on Thursday, 17 November 2022. The presentation will be live-streamed on the following link<\/a>, and a recording will be made available shortly after on the Investor Portal<\/a> of BenevolentAI\u2019s website.\n<\/p>\n

\nBenevolentAI\u2019s management, investor relations and business development team will be attending and available throughout the conference for meetings.\n<\/p>\n

\nAbout BenevolentAI<\/b>\n<\/p>\n

\nBenevolentAI (AMS: BAI) is a leading, clinical-stage AI-enabled drug discovery and development company listed on the Euronext Amsterdam stock exchange. Through the combined capabilities of its AI platform, scientific expertise, and wet-lab facilities, BenevolentAI is well-positioned to deliver novel drug candidates with a higher probability of clinical success than those developed using traditional methods. The Benevolent Platform\u2122 powers a growing in-house pipeline of 13 named drug programmes and over 10 exploratory programmes, and it maintains successful collaborations with AstraZeneca, as well as leading research and charitable institutions. BenevolentAI is headquartered in London, with a research facility in Cambridge (UK) and a further office in New York.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestors<\/b>
Fleur Wood – Investor Relations
\n
investors@benevolent.ai<\/a><\/p>\n

Media<\/b>
Rajin Kang – VP Communications
\n
press@benevolent.ai<\/a><\/p>\n

Business Development<\/b>
Catherine Tucker
\n
bd@benevolent.ai<\/a><\/p>\n

FTI Consulting:<\/b>
Ben Atwell, Simon Conway, Victoria Foster Mitchell
\n
BenevolentAI@fticonsulting.com<\/a>
+44 (0) 20 3727 1000\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

LONDON–(BUSINESS WIRE)–BenevolentAI \u200b\u200b(Euronext Amsterdam: BAI), a leading clinical-stage AI drug discovery company, announces that it will participate at the upcoming Jefferies London Healthcare Conference from 15-17 November. Nick Keher, Chief Financial Officer of BenevolentAI is scheduled to present at 10.20 AM GMT on Thursday, 17 November 2022. The presentation will be live-streamed on the following … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-50487","6":"format-standard","7":"category-industry"},"yoast_head":"\nBenevolentAI to present at Jefferies Investor Conference in November - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/benevolentai-to-present-at-jefferies-investor-conference-in-november\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BenevolentAI to present at Jefferies Investor Conference in November - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"LONDON–(BUSINESS WIRE)–BenevolentAI \u200b\u200b(Euronext Amsterdam: BAI), a leading clinical-stage AI drug discovery company, announces that it will participate at the upcoming Jefferies London Healthcare Conference from 15-17 November. Nick Keher, Chief Financial Officer of BenevolentAI is scheduled to present at 10.20 AM GMT on Thursday, 17 November 2022. The presentation will be live-streamed on the following ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/benevolentai-to-present-at-jefferies-investor-conference-in-november\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-04T06:02:35+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/benevolentai-to-present-at-jefferies-investor-conference-in-november\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/benevolentai-to-present-at-jefferies-investor-conference-in-november\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"BenevolentAI to present at Jefferies Investor Conference in November\",\"datePublished\":\"2022-11-04T06:02:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/benevolentai-to-present-at-jefferies-investor-conference-in-november\\\/\"},\"wordCount\":244,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/benevolentai-to-present-at-jefferies-investor-conference-in-november\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/benevolentai-to-present-at-jefferies-investor-conference-in-november\\\/\",\"name\":\"BenevolentAI to present at Jefferies Investor Conference in November - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2022-11-04T06:02:35+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/benevolentai-to-present-at-jefferies-investor-conference-in-november\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/benevolentai-to-present-at-jefferies-investor-conference-in-november\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/benevolentai-to-present-at-jefferies-investor-conference-in-november\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BenevolentAI to present at Jefferies Investor Conference in November\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BenevolentAI to present at Jefferies Investor Conference in November - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/benevolentai-to-present-at-jefferies-investor-conference-in-november\/","og_locale":"en_US","og_type":"article","og_title":"BenevolentAI to present at Jefferies Investor Conference in November - Pharma Trend","og_description":"LONDON–(BUSINESS WIRE)–BenevolentAI \u200b\u200b(Euronext Amsterdam: BAI), a leading clinical-stage AI drug discovery company, announces that it will participate at the upcoming Jefferies London Healthcare Conference from 15-17 November. Nick Keher, Chief Financial Officer of BenevolentAI is scheduled to present at 10.20 AM GMT on Thursday, 17 November 2022. The presentation will be live-streamed on the following ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/benevolentai-to-present-at-jefferies-investor-conference-in-november\/","og_site_name":"Pharma Trend","article_published_time":"2022-11-04T06:02:35+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/benevolentai-to-present-at-jefferies-investor-conference-in-november\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/benevolentai-to-present-at-jefferies-investor-conference-in-november\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"BenevolentAI to present at Jefferies Investor Conference in November","datePublished":"2022-11-04T06:02:35+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/benevolentai-to-present-at-jefferies-investor-conference-in-november\/"},"wordCount":244,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/benevolentai-to-present-at-jefferies-investor-conference-in-november\/","url":"https:\/\/pharma-trend.com\/en\/benevolentai-to-present-at-jefferies-investor-conference-in-november\/","name":"BenevolentAI to present at Jefferies Investor Conference in November - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2022-11-04T06:02:35+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/benevolentai-to-present-at-jefferies-investor-conference-in-november\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/benevolentai-to-present-at-jefferies-investor-conference-in-november\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/benevolentai-to-present-at-jefferies-investor-conference-in-november\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"BenevolentAI to present at Jefferies Investor Conference in November"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50487","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=50487"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50487\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=50487"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=50487"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=50487"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}